Vitamin D Receptor (VDR or Calcitriol Receptor) Agonist Drug Pipeline Insight Market Report 2022 Featuring Hybrigenics, MC2 Therapeutics, Lipidor/Cerbios-Pharma, OPKO Renal, & Chugai Pharmaceutical - ResearchAndMarkets.com
Retrieved on:
Wednesday, February 9, 2022
The "Vitamin D Receptor (VDR or Calcitriol Receptor) Agonist - Pipeline Insight, 2022" clinical trials has been added to ResearchAndMarkets.com's offering.
Key Points:
- The "Vitamin D Receptor (VDR or Calcitriol Receptor) Agonist - Pipeline Insight, 2022" clinical trials has been added to ResearchAndMarkets.com's offering.
- "Vitamin D Receptor (VDR or Calcitriol Receptor) Agonist - Pipeline Insight, 2022" report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Vitamin D Receptor (VDR or Calcitriol Receptor) Agonist development.
- The report assesses the active Vitamin D Receptor (VDR or Calcitriol Receptor) Agonist pipeline products by developmental stage, product type, molecule type, and administration route.
- Offers detailed therapeutic product profiles of Vitamin D Receptor (VDR or Calcitriol Receptor) Agonist with key coverage of developmental activities including licensing & collaboration deals, patent details, designations, technologies, indications and chemical information
Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration